• Disclaimer
  • Privacy Policy
Media Coverage
  • Analyst Ratings
  • Market coverage
  • Business news
  • Wealth
  • Stock Markets
  • World Economy
  • About Us
    • About us
    • Contact
No Result
View All Result
  • Analyst Ratings
  • Market coverage
  • Business news
  • Wealth
  • Stock Markets
  • World Economy
  • About Us
    • About us
    • Contact
No Result
View All Result
Media Coverage
No Result
View All Result
Home World Economy

LeMaitre Vascular Stock: Recent Ratings, Earnings report, and Future Growth Opportunities

Elaine Mendonça by Elaine Mendonça
May 7, 2023
in World Economy
0
Finance stock investing (2)
0
SHARES
8
VIEWS
Share on FacebookShare on Twitter

As of May 6, 2023, LeMaitre Vascular (NASDAQ:LMAT) stock opened at $65.23, with a market capitalization of $1.44 billion. With its current P/E ratio of 70.14 and PEG ratio of 5.40, the medical instruments supplier’s stock has been under the watchful eyes of multiple brokerages.

According to a report by Roth Capital on March 7th, a “neutral” rating was reaffirmed for shares of LeMaitre Vascular. However, on April 9th, StockNews.com upgraded the stock from a “hold” rating to a “buy” rating while Barrington Research further upgraded it from a “market perform” rating to an “outperform” one with a price objective set at $62.00 for the company.

In other news, insider Trent G. Kamke sold over six thousand shares on March 3rd at an average price of $50.94 per share amounting to over three hundred thousand dollars in total value. As per SEC regulations, this transaction was disclosed publicly.

On Tuesday, May 2nd LeMaitre posted its quarterly earnings data revealing an EPS (earnings per share) of $0.27 for the quarter which surpassed consensus estimates by two cents demonstrating promising growth since the same quarter last year where EPS also stood at $0.27.

With all things considered and positive outlooks surrounding LMAT’s earnings report it appears that investors looking for quality medical instrument suppliers will have more confidence in their investments moving forward with LeMaitre being positioned well for continued growth both post-COVID and into tomorrow’s technological landscape as well as China’s expanding market opportunities- all forecasts suggest LMAT will only continue growing strong in years to come making now potentially an ideal time to invest in future prospects offered by this dynamic firm while valuations are still within reasonable range.

LeMaitre Vascular, Inc. Receives Optimistic Earnings Estimate Revisions and Declares Quarterly Dividend



The medical instruments supplier, LeMaitre Vascular, Inc. (NASDAQ:LMAT), has recently been the recipient of an optimistic note issued by equities researchers at KeyCorp. The note voted in favor of a revised FY2023 earnings estimate for LeMaitre Vascular, projected to increase earnings per share from $1.16 to $1.17 for the year. While this may seem like a meager amount, it’s quite significant news for the company and its investors.

Following up on the recent announcement, KeyCorp also released estimates for LeMaitre Vascular’s FY2024 earnings at an estimated EPS worth $1.41. This is welcome news after the past quarters had been somewhat lackluster for the medical instruments subsidiary.

In line with their increasing profitability, the company also declared a recent quarterly dividend with effect from Thursday, June 1st, much to the satisfaction of investors. For quarter-on-quarter performance updates: investors of record on Wednesday May 17th will be eligible for a $0.14 per share payout come June 1st. It’s worth noting that one has to purchase shares before Tuesday May 16th -the ex-dividend date- in order to receive these incentives.

The annualized dividend for LeMaitre Vascular comes out to be around $0.56 per share with a yield of about 0.86%. This type of reward provides extra incentive when holding onto stocks long-term, while simultaneously decreasing investment risk since dividends can provide an income stream even if market conditions are unfavorable or bearish.

KeyCorp analysts are likely pleased by this upturn in prospects at LeMaitre Vascular as it helps solidify their standing within other players in their industry and demonstrates improved financial performance overall; which most certainly sends positive signals to new buyers who are looking into examining their portfolio diversification options.

With these freshly updated figures from KeyCorp, it’s an encouraging sign for investors who believe in LeMaitre Vascular’s long-term growth and potential as medical instrument suppliers. It’s more than apparent that they are increasing value for all stakeholders involved.

Tags: LMAT
Previous Post

Glenview Trust Co Trims Stake in Eli Lilly and Company: Analysts Weigh In on LLY Shares

Next Post

Glenview Trust Co Increases Stake in Lockheed Martin Co, Demonstrates Confidence in Aerospace Giant’s Potential

Next Post
Finance stock investing

Glenview Trust Co Increases Stake in Lockheed Martin Co, Demonstrates Confidence in Aerospace Giant's Potential

Wealth

Sugarhill Ddot’s Net Worth: Inside The Career of the Rising Drill Rap Star

by Gabriel Bello Obando
November 10, 2023
0

When it comes to the hip-hop scene in America, there are a few names that stand out. However, one name...

Read more

From Telenovelas to Hollywood: Exploring Kate del Castillo Net Worth and Career Achievements

June 1, 2023

Adamari López Net Worth: An Inspirational Tale of Resilience Beyond The Screen

June 1, 2023

Simon Helberg Net Worth: A Multi-Talented Hollywood Star

June 1, 2023

Sam Bailey Net Worth: Her Journey to Fame and Musical Career

June 1, 2023

Categories

  • Analyst Ratings
  • Business
  • Business news
  • Market coverage
  • Pre-IPO & Startups
  • Stock Markets
  • Wealth
  • World Economy

About Us

Our team of experienced journalists and industry experts is committed to providing you with the latest and most accurate information on a wide range of topics, from finance and technology to politics and the economy.

We are proud to be part of the Best Stocks team and to offer our readers exceptional content that is informed by our combined expertise. We look forward to continuing to serve our readers and to playing a key role in the world of business analysis and reporting.

READ MORE

  • Media Contacts
  • Journalist Contacts
  • Contact
  • About us
  • Disclaimer
  • Privacy Policy

© 2023 Media Coverage

No Result
View All Result
  • Analyst Ratings
  • Market coverage
  • Business news
  • Wealth
  • Stock Markets
  • World Economy
  • About Us
    • About us
    • Contact

© 2023 Media Coverage